Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 6/20 | 0.47 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.47 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7737577 | 0.87 | TSHR (0.46) | AKR1B1AKR1B10AKR1A1TSHRTDP1 | |
| SCHEMBL17604736 | 0.80 | AKR1B1 (0.40) | AKR1B1AKR1B10AKR1A1TSHRTDP1 | |
| SCHEMBL10602986 | 0.80 | TSHR (0.49) | AKR1B1AKR1B10AKR1A1TSHRTDP1 | |
| SCHEMBL17604915 | 0.78 | AKR1B1 (0.52) | AKR1B1TSHRTDP1ITGA4 | |
| SCHEMBL10601680 | 0.77 | TSHR (0.49) | AKR1B1AKR1A1TSHRTDP1ITGA4 | |
| SCHEMBL7739979 | 0.76 | HSD11B1 (0.43) | AKR1B1AKR1B10AKR1A1TSHRTDP1 | |
| SCHEMBL10604506 | 0.74 | TSHR (0.47) | AKR1B1AKR1B10AKR1A1TSHRTDP1 | |
| SCHEMBL10604226 | 0.72 | TSHR (0.55) | AKR1B1TSHRTDP1ITGA4 | |
| SCHEMBL11111384 | 0.70 | TSHR (0.71) | AKR1B1TSHRTDP1 | |
| SCHEMBL30062196 | 0.68 | TSHR (0.49) | AKR1B1TSHRTDP1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016044770-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | AKR1B1 84/4885AKR1B10 236/4885AKR1A1 106/4885 |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, KAT2A | AKR1B1 69/4885AKR1B10 165/4885AKR1A1 88/4885 |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | AKR1B1 84/4885AKR1B10 236/4885AKR1A1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.